Clinical Trial Update: Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating dual sympathetic nerve blocks for sympathetically mediated symptoms in long COVID/post-COVID conditions has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dysautonomia
• Orthostatic Hypotension Syndrome
• Post-acute Sequelae of Sars-cov-2 Infection
• Post-covid-19 Condition

Snippet

Sponsor: Jonathann Kuo, MD | Conditions: Post Acute COVID-19 Syndrome, Long COVID | Phase 1 | Status: COMPLETED